drugset / Trial / NCT03860220

The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin

NCT03860220

Phase 4 Completed 252 enrolled Hyo-Soo Kim
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this study was to assess the efficacy and safety of FDC therapy with triple therapy of Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10mg in Korean patients with both hypertension and dyslipidemia.

Timeline

Start
2019-04-25
Primary completion
2023-09-07
Completion
2023-09-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 10 mg
Comparator Telmisartan Other / unclassified 40 mg
Comparator Amlodipine Other / unclassified 5 mg